Anatara Lifesciences provided an update on progress of clinical trials in psychological functioning and irritable bowel syndrome, diarrhoea subtype (IBS-D). The Company also provides a brief operational update. Human clinical trials for IBS-D (GaRP) and psychological functioning (3FDC) Globally there is a high prevalence of digestive disorders requiring relief from both symptoms and the disease process, including irritable bowel syndrome (IBS).

There is also increasing interest in the "gut- brain" axis and the influences of the microbiome. The GaRP and 3FDC complementary medicines provide a significant market opportunity to address these considerations whilst improving individuals' quality of life. The revised protocol for the IBS trial expands eligibility to all IBS subtypes other than IBS-C (constipation subtype).

It required minor adjustments to the primary and secondary endpoints. With this change, the company will be able to re-screen more than 300 potential participants who were unable to enrol due to not having diarrhoea predominant IBS. The changed protocol will be updated in the recruitment website and the Obvio Health ClaimIt online portal and mobile app by 27 June.

The revised protocol for the psychological functioning expands eligibility to participants with scores in the moderate range on a minimum of one of the DASS-21 subscales to also include participants with scores in the mild range on a minimum of two of the DASS-21 subscales.